Top

Clinical and Translational Oncology

Published in:

01-09-2012 | Research Article

Searching for Hif1-α interacting proteins in renal cell carcinoma

Authors: V. Medina Villaamil, G. Aparicio Gallego, I. Santamarina Caínzos, M. Valladares-Ayerbes, L. M. Antón Aparicio

Published in: Clinical and Translational Oncology | Issue 9/2012

Abstract

Introduction

Kidney tumours are frequently characterised by hypoxic conditions due to a local imbalance between oxygen (O₂) supply and consumption. Hif1-α regulates angiogenesis, tumour growth, tumour progression, metastatic spread, and glucose metabolism by acting as a transcription factor for relevant genes. Here, we describe an immunohistochemical study of Hif1-α, a comprehensive computational study of Hif1-α interacting proteins (HIPs), an analysis correlating expression levels of Hif1-α with upstream and downstream proteins, and an analysis of the utility of Hif1-α for prognosis in a cohort of patients with renal cell carcinoma.

Materials and methods

The patient cohort included 80 patients. For immunohistochemistry evaluation, tissue microarrays were constructed. The IntAct, MINT, and BOND databases were used for the HIP approach. The Kruskal–Wallis test was used for comparing protein expression with pathology measurements. Correlation was expressed as the Pearson coefficient.

Results

Hif1-α expression correlates significantly with the “clear” histological subtype of renal cell carcinoma (p < 0.01). The samples with the worst prognoses related to the pathological variables analysed showed the highest levels of Hif1-α expression. Significant correlations were found with Bcl-2, CAIX, C-kit, EGFR, TGF-β, proteins of the VEGF family, proteins related to differentiation (such as Notch1 and Notch3) and certain metabolic enzymes. Bioinformatic analysis suggested 45 evidence-based HIPs and 4 complexes involving protein Hif1-α.

Conclusions

This work summarises the multifaceted role of Hif1-α in the pathology of renal cell carcinomas, and it identifies HIPs that could help provide mechanistic explanations for the different behaviours seen in tumours.

Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239PubMedCrossRef

Audenet F, Yates DR, Cancel-Tassin G et al (2011) Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 109:1864–1870PubMedCrossRef

Fraga A, Ribeiro R, Medeiros R (2009) Tumor hypoxia: the role of HIF. Actas Urol Esp 33:941–951PubMedCrossRef

Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009–1014PubMedCrossRef

Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef

Medina Villaamil V, Alvarez García A, Aparicio Gallego G et al (2011) Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep 4:451–457

Aranda B, Achuthan P, Alam-Faruque Y et al (2010) The IntAct molecular interaction database in 2010. Nucleic Acid Res 38:D525–D531PubMedCrossRef

Ceol A, Aryamontri A, Licata L et al (2009) MINT, the molecular interaction database: 2009 update. Nucleic Acid Res 38:D532–D539PubMedCrossRef

Alfarano C, Andrade CE, Anthony K et al (2005) The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acid Res 33:D418–D424PubMedCrossRef

10.

Hägele S, Behnam B, Borter E et al (2006) TSGA10 prevents nuclear localization of the hypoxia-inducible factor (HIF)-1alpha. FEBS Lett 580:3731–3738PubMedCrossRef

11.

Reddy S, Pakala S, Ohshiro K et al (2009) MicroRNA-661, a c/EBP-alpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Res 69:5639–5642PubMedCrossRef

12.

Nordstrom-O’Brien M, van der Luijt R, van Rooijen E et al (2010) Genetic analysis of von Hippel-Lindau disease. Hum Mutat 31:521–537PubMed

13.

Jeong J, Bae M, Ahn M-Y et al (2002) Regulation and destabilization of HIF-1 alpha by ARD1-mediated acetylation. Cell 111:709–720PubMedCrossRef

14.

Sobulo O, Borrow J, Tomek R et al (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Nat Acad Sci 94:8732–8737PubMedCrossRef

15.

Kamal A, Thao L, Sensintaffar J et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407–410PubMedCrossRef

16.

Cerchietti L, Lopes E, Yang S et al (2009) A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Med 15:1369–1376PubMedCrossRef

17.

Deniaud E, Baguet J, Mathieu A-L et al (2006) Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 25:7096–7105PubMedCrossRef

18.

Pause A, Lee S, Worrell R et al (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Nat Acad Sci 94:2156–2161PubMedCrossRef

19.

Hakimi M-A, Dong Y, Lane W et al (2003) A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem 278:7234–7239PubMedCrossRef

20.

Noonan E, Place R, Pookot D et al (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28:1714–1724PubMedCrossRef

21.

Mahon P, Hirota K, Semenza G (2001) FIH-1: a novel protein that interacts with HIF-1-alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675–2686PubMedCrossRef

22.

Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMed

23.

Pantuck AJ, Zeng G, Belldegrun AS et al (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641–4652PubMed

24.

Lidgren A, Hedberg Y, Grankvist K et al (2005) The expression of hypoxia-inducible factor 1α is a favourable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11:1129–1135PubMed

25.

Rink M, Chun FK, Robinson B et al (2011) Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 63:293–308PubMed

26.

Di Cristofano C, Minervini A, Menicagli M et al (2007) Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol 31:1875–1881PubMedCrossRef

27.

Dorai T, Sawczuk I, Pastorek J et al (2006) Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 24:754–779PubMedCrossRef

28.

Grabmaier K, De Weijert MCA, Verhaegh GW et al (2004) Strict regulation of CAIX (G250/MN) by Hif1-α in clear cell renal cell carcinoma. Oncogene 23:5624–5631PubMedCrossRef

29.

Greijer AE, van der Greijer WE (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57:1009–1014PubMedCrossRef

30.

Medina V, Aparicio G, Valbuena L et al (2011) Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol Rep 25:315–323

31.

Chen Y, De Marco MA, Graziani I et al (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67:7954–7959PubMedCrossRef

32.

Sahlgren C, Gustafsson MV, Jin S et al (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105:6392–6397PubMedCrossRef

33.

Bedogni B, Warneke JA, Nickoloff BJ et al (2008) Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118:3660–3670PubMedCrossRef

34.

Lin P, Wang W, Cai WJ et al (2009) Relationship between the expression of hypoxia-inducible factor-1alpha and epidermal growth factor receptor and micro vessel density and their clinical significance. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44:480–485PubMed

35.

Pan CC, Chen P, Chiang H (2004) Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 121:878–883PubMedCrossRef

36.

Johnson DW, Berg JN, Baldwin MA et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189–195PubMedCrossRef

37.

Oh SP, Seki T, Goss KA et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97:2626–2631PubMedCrossRef

38.

Burrows FJ, Derbyshire EJ, Tazzari PL et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1:1623–1634PubMed

39.

Goumans MJ, Valdimarsdottir G, Itoh S et al (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 21:1743–1753PubMedCrossRef

40.

Zhang X, Zhang R, Jiang Y et al (2011) The expanded human disease network combining protein–protein interaction information. Eur J Hum Genet 19:783–788PubMedCrossRef

Title: Searching for Hif1-α interacting proteins in renal cell carcinoma
Authors: V. Medina Villaamil
G. Aparicio Gallego
I. Santamarina Caínzos
M. Valladares-Ayerbes
L. M. Antón Aparicio
Publication date: 01-09-2012
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0857-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2012

In answer to: “Comments to SEOM clinical guidelines for the treatment of thyroid cancer” by Garcilaso Riesco-Eizaguirre et al

Comments to SEOM clinical guidelines for the treatment of thyroid cancer

Chemotherapy at the end of life: up until when?

Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation

Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer